São Paulo, Brazil — On July 17–31, 2025, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (referred to as "VitaFlow Liberty^®"), independently developed by MicroPort CardioFlow Medtech Corporation (02160.HK), successfully completed Brazil’s first 7 commercial clinical cases at Santa Casa de São Paulo.

As one of Brazil’s oldest charitable hospitals, Santa Casa de São Paulo has long been renowned for its excellence in medical care and academic influence. All seven procedures were performed under the guidance of renowned Argentine cardiovascular interventional expert Prof. Matías Sztefman, with Prof. José Mariani, Prof. Eduardo Pessoa, Prof. Edgar Quintella, Prof. Guy Prado, Prof. Pedro Lemos, and Prof. Ricardo Ghetti leading the operations. Postoperative evaluations confirmed no significant paravalvular leakage or complications, with all cases achieving complete success.

The surgical team expressed high satisfaction with the clinical performance of VitaFlow Liberty^®. Multiple operators noted: "The hybrid-density design of this valve stent provides sufficient radial force, offering a distinct advantage in TAVI procedures for highly calcified aortic valve lesions. Additionally, the electric retrievable system is highly user-friendly, enabling precise and stable valve deployment. We look forward to bringing this product to more Brazilian patients."

The successful completion of Brazil’s first 7 commercial cases within just two months of VitaFlow Liberty^®’s launch—marking its entry into Latin America’s largest healthcare market—not only validates the product’s clinical strengths but also injects strong momentum into CardioFlow’s global strategy. Moving forward, the company will deepen innovation, accelerate expansion into high-potential, high-growth overseas markets, and empower broader patient populations worldwide with China-developed premium medical devices, contributing more "Chinese solutions" to global healthcare.